Research Milestone Payments. 6.2.1 NCE IDENTIFICATION. RWJPRI shall pay the following amounts to KOSAN within [**] following accomplishment of the following Research Milestones in connection with the Research PROJECTS: $[**] Identification of a [**] in the FAST TRACK PROJECT $[**] Identification of each [**] in the SAR PROJECT
Research Milestone Payments. In connection with the research and preclinical Development of Discovered RNAi Compounds directed against Selected Targets, Novartis shall pay, or cause to be paid, to Alnylam the following one-time payments with respect to each Selected Target upon the achievement of the milestone events set forth below:
Research Milestone Payments. In addition to the payments outlined in Sections 5.1(a) through (d), PFIZER shall pay to XXXXX the following amounts pursuant to this Section 5.1(e) with respect to each of the Research Compounds (collectively, the “Research Compound Milestone Payments”) upon satisfaction in full of the applicable events described under the column titled “Research Regulatory Events” (each a “Research Regulatory Event”). The Research Compound Milestone Payments shall only be paid once per Research Compound per Research Regulatory Event, without regard to the Indication, number of Indications for which such Licensed Product containing the Research Compound is approved or whether a Research Product, Research Combination Product or Research Vaccine Product is involved. PFIZER shall pay to XXXXX the Research Compound Milestone Payments pursuant to this Section 5.1(e) even if the Milestone Ceiling set forth in Section 5.1(d)(ii)(D) has been met.
(1) Acceptance for filing of [**************************** ***************************** *******************************************] [**********]
(2) Commencement of [********** ****************************** *********************************************] [**********]
(3) Acceptance of filing of [********************* ********************************************* ********************************************** *********************************] [**********]
(4) [*******] (i) [************************** *************************] (ii) [************* ******************************************* *******************************************] (iii) [*************************************** *********************************] [**********]
Research Milestone Payments. The following milestone amounts (the “Research Milestone Payments”) shall be paid by ONO to Receptos in case of achievement of each of the events specified below (the “Research Milestone Events”) which shall not be subject to modification by the JRC. In case that Alternative Target becomes the new Collaboration Target and if the Target Exclusivity Period of the original Collaboration Target (***) remains effective at the time of their achievement, the Research Milestones Payment for Research Milestone Events No. 8 and No. 9 specified in this Section 6.3 with respect to original Collaboration Target shall remain payable by ONO to Receptos in addition to any Research Milestone Payments achieved with respect to the new Collaboration Target. 1 Expressed Collaboration Target No less than 0.5 mg/mL recoverable protein $ *** 2 Establishment of *** *** $ *** 3 Initial Crystallography of Collaboration Target with any *** Solution for Collaboration Target with *** $ *** 4 2nd Crystallography of Collaboration Target with any *** $ *** 5 3rd Crystallography of Collaboration Target with any *** $ *** 6 4th Crystallography of Collaboration Target with any *** $ *** 7 5th Crystallography of Collaboration Target with any *** $ *** TOTAL CRYSTALLOGRAPHY RESEARCH MILESTONES $ *** 8 Upon identification by ONO of the first Lead Compound, provided such event occurs after the achievement of Initial Collaboration Success and, subject to Section 6.3.4, during the Research Term. $ *** 9 Upon filing of the first Patent application of Collaboration Compound IP where the priority for the patent application supporting a claim directed to a Collaboration Compound or a method of use thereof in the Field is subsequent to the date of Initial Collaboration Success and during the Research Term. $ *** TOTAL CHEMISTRY RESEARCH MILESTONES $ ***
Research Milestone Payments within thirty (30) days of the date of achievement of the applicable milestone during the Term of the Collaboration, OSIP will pay to SGX the following non-refundable milestone payments; provided however, that OSIP will not be required to pay under this Section 3.3 for more than [...***...] ([...***...]) milestones (i.e. $[...***..
Research Milestone Payments. AHP will promptly notify the Joint Research Committee upon the accomplishment of the research milestones set forth in EXHIBIT B ("Research Milestones"), which notification shall be accompanied by such supporting information as to allow the Joint Research Committee to confirm the accomplishment of such Research Milestone. Subject to the provisions of Section 4.9, of the Joint Research Committee shall, within *** days of receipt of such notification, determine whether the Research Milestone described in such notification has been accomplished and shall report its findings to both parties. If the Joint Research Committee determines that a Research Milestone has been accomplished, *** following the receipt of notification by the Joint Research Committee of such accomplishment, AHP shall make the corresponding milestone payment set forth in EXHIBIT B; *** . Any determination of the Joint Research Committee pursuant to Section 4.1.2 shall also serve as such determination of the Joint Research Committee for the purposes of this Section.
Research Milestone Payments. Vertex shall make research milestone payments to Alios based on achievement of research milestones set forth below. Except as provided below, Vertex shall pay the amounts set forth below within [***] after first achievement of [***], as applicable. Each [***] by Vertex to Alios hereunder shall be non-creditable and non-refundable. After payment of the [***], there shall be no further milestones payable by Vertex upon [***].
Research Milestone Payments. Within sixty (60) days of the date of achievement of the applicable Milestone during the Term of the Collaboration, Serono will pay, or cause to be paid, to SGX the following non-refundable Milestone payments, on a Serono Target-by-Serono Target basis: MILESTONES AMOUNT ---------- ------ (a) Completion of [...***...] for a Serono Target U.S. $[...***...] per Serono Target ***CONFIDENTIAL TREATMENT REQUESTED
Research Milestone Payments. Each Year for the first five (5) Years ---------------------------- following the Effective Date, NEI shall pay to Diversa research milestones in accordance with the Project Plans for each Project. Such research milestone payments shall not exceed [*****] of the total costs of all research FTEs for each Year, as set forth under the column headed "Total Research FTEs" in Section 6.3 of the Joint Venture Agreement (the "Maximum Annual Milestones"). In any event, each Year for the first [*****] following the Effective Date, NEI shall pay to Diversa guaranteed research milestones equal to [*****] of the Maximum Annual Milestones for such Year. Research milestone payments under this Section 6.3 shall be non-refundable and shall not be credited against any other payments payable to Diversa under this Agreement or under the Joint Venture Agreement.
Research Milestone Payments. (a) With respect to each Designated Target and subject to Section 3.2.3(f), Takeda shall pay to Denali, in accordance with Sections 8.4 and 8.8, the milestone payments set forth below following the first achievement of each corresponding research milestone event set forth below (each, a “Research Milestone”) with respect to the [***] to achieve the applicable stage of development:
1. The Initiation of activities to [***] $5,000,000 (subject to Section 8.2.1(b)) [***] [***] [***] [***] Confidential 66 *** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request.
(b) With respect to [***] and the achievement of Research Milestone 1, [***] shall be payable upon the [***] and [***] shall be payable upon [***].
(c) With respect to the Research Milestones for each Designated Target, if Research Milestone 2 or 3 is achieved before a milestone payment has been made with respect to a lower-numbered Research Milestone, or if a Development Milestone is achieved by an Optioned Biologic or Optioned Product directed to such Designated Target before a milestone payment has been made with respect to one or more Research Milestone for such Designated Target, then all milestone payments corresponding to such lower-numbered Research Milestones for such Designated Target shall be deemed achieved upon achievement of the subsequent Research Milestone or Development Milestone, as applicable. Notwithstanding the foregoing, with respect to a particular Research Program, if [***], then [***].
(d) For the avoidance of doubt, a Research Milestone may be achieved after the Option Exercise Date with respect to the applicable Collaboration Program.
(e) Each Research Milestone is payable [***] with respect to each Designated Target, regardless of how many Research Biologics meet such milestone event, and no Research Milestone payment shall be made more than [***] times under this Agreement. The total amount payable by Takeda to Denali under this Section 8.2.1 shall not exceed (i) Twenty-Five Million Dollars ($25,000,000) with respect to each Designated Target and (ii) Seventy-Five Million Dollars ($75,000,000) in the aggregate. In the event the Parties replace any Designated Target with a Replacement Designated Target, then Takeda shall not be required to make any Research Milestone Payment with respect to such Replacement Desig...
